Problem:
Nonalcoholic steatohepatitis (NASH) is an advancing pathological condition of the liver that lacks an authorized therapeutic intervention. Resmetirom is an oral, liver-specific, target thyroid hormone receptor beta agonist now being developed for the treatment of non-alcoholic steatohepatitis (NASH) complicated with liver fibrosis. This trial is a phase 3 study that includes people with proven nonalcoholic steatohepatitis (NASH) with a fibrosis stage of F1B, F2, or F3, with fibrosis extending up to F4 (cirrhosis). Patients were allocated at random in a 1:1:1 ratio to receive resmetirom once daily at a dosage of 80 mg, 100 mg, or an inactive placebo. This study, the MAESTRO-NASH trial, aimed to assess if Resmetirom could enhance liver outcomes by resolving NASH without exacerbating fibrosis and lowering fibrosis by at least one stage without complicating NASH.